Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Looking Ahead: Anticipating Changes in Lupus Guidelines and Clinical Practice
Amit Saxena, MD, discusses how personalized treatment decisions for lupus nephritis require careful consideration of patient characteristics, multidisciplinary coordination, and emerging guidelines, while acknowledging both the opportunities and challenges that lie ahead in clinical practice.
EP: 1.Understanding the Clinical Burden and Prevalence of Lupus Nephritis
EP: 2.Cost Drivers in Lupus Nephritis
EP: 3.Urgency to Treat in Lupus Nephritis: Goals of Therapy and Early Diagnosis Strategies
EP: 4.Guideline Updates in Lupus Nephritis: Impacts on Clinical Decision-Making
EP: 5.Tailoring Lupus Nephritis Treatment: Key Considerations and Specialist Approaches
EP: 6.Belimumab and Voclosporin: Clinical Insights and Payer Evaluations in Lupus Nephritis
EP: 7.Improving Access to Lupus Nephritis Treatment: Strategies and Resources
EP: 8.Lupus Nephritis Management: Monitoring Strategies and Long-Term Study Results
EP: 9.Collaborating for Better Care: Healthcare Providers and Payers in Lupus Nephritis
EP: 10.From Guidelines to Practice: Advancing Lupus Nephritis Treatment
Now Viewing
EP: 11.Looking Ahead: Anticipating Changes in Lupus Guidelines and Clinical Practice
Video content above is prompted by the following:
- What considerations (eg, individual patient characteristics, steroid use, drug interactions) guide your treatment choices for managing lupus nephritis?
- How important is multidisciplinary care in managing lupus nephritis, and how do you coordinate this?
- The ACR is working on a 2-part lupus guideline project expected next year. In what ways do you see these guidelines evolving in the future?
- What specific opportunities or challenges do you see on the horizon for managing lupus nephritis in practice?
Related Videos
Related Content
FDA Expands Access to Approved CAR T-Cell Therapies by Eliminating REMS
June 30th 2025Article
The FDA has removed Risk Evaluation and Mitigation Strategies (REMS) for approved chimeric antigen receptor (CAR) T-cell therapies for hematologic malignancies, aiming to ease provider burden and expand patient access.
Read More
